Request addressed:  
Summarize what can and cannot be supported from the current local data context, user-provided metabolomics, scRNA‑seq, public dataset analyses, and metabolic‑evidence package. Focus on the mandatory gene expression checks for MK/platelet cluster, the central AMD1‑polyamine and Pnp‑inosine/adenosine chains, and the revived matricellular/secretome axis. Identify explicit evidence gaps for pathway‑level, tissue‑level, and whole‑lung metabolite cross‑check.

Search or analysis performed:  
Inspected the provided single‑cell summary (`seurat_merged.rds` summary), user metabolomics (`sFig6A Raw data.xlsx` for MK‑sorted metabolites, `Figure6D+F raw data.xlsx` for whole‑lung metabolites), the metabolomics‑to‑mechanism evidence package with ranked chains, the public dataset analysis context (GSE289322 and GSE291455 completed analyses but results not displayed), and the prior generation agents’ self‑reported Seurat expression tables. Cross‑referenced the mandatory gene list against all available data sources.

---

### Key findings

#### 1. Mandatory Seurat gene expression in MK/platelet cluster (PH vs control)

- **Finding:** Expression and differential status for *Pdgfb, Tgfb1, F3, Thbs1, Glo1, Rab27a, Tsg101, Cd44, Lox, Loxl1, Loxl2, Mki67* were not directly retrieved by the Tool Use Agent; they are available only as self‑reported tables in the prior generation agents’ outputs.
- **Evidence type:** Indirect – second‑hand reports from generation agents (generation_1 provided a detailed table; other agents cited similar trends).  
- **Source:** Generation agent outputs within the current context; original Seurat queries were performed by those agents outside the Tool Use Agent’s direct view.  
- **Relevance to MK‑hypoxia‑vascular remodeling direction:** Critical, because these genes define the proposed “matricellular/coagulation/EV secretome” axis (Axis6/Revived_Matricellular) and inform EV‑biogenesis capacity, ECM cross‑linking potential, and proliferation status in MKs.  
- **Strength:** The reports consistently claim that *Pdgfb, Tgfb1, Thbs1, F3, Rab27a, Tsg101, Cd44, Lox* are expressed in MKs and show hypoxia‑induced upregulation (*Pdgfb* up, *Thbs1* up >1.5 log2FC, *F3* up ~1.5, *Tgfb1* up ~1.2, *Rab27a* upregulated, *Tsg101* modest increase, *Cd44* moderate increase, *Lox* up; *Loxl2* modest, *Loxl1* not explicitly detailed). *Mki67* low/no change, *Glo1* expressed but not hypoxia‑up.
- **Limitation:** These values have not been independently verified by the Tool Use Agent; precise log2FC, p‑values, and detection rates are missing from the current local context. The mandatory check for *Amd1* protein‑level surrogates was not addressed. Therefore, the functional axis built on these genes must be treated as **provisionally supported by self‑reported expression data**, not by directly accessible user data in this summary.

**Mandatory gene results summary (from generation agents):**

| Gene | MK expression reported? | PH‑vs‑control change reported? | Note |
|------|-------------------------|--------------------------------|------|
| *Pdgfb* | Yes | Up (log2FC > 1) | |
| *Tgfb1* | Yes | Up (~1.2) | |
| *F3* | Yes | Up (~1.5) | |
| *Thbs1* | Highly expressed | Up (>1.5) | |
| *Glo1* | Expressed | Not up | |
| *Rab27a* | Enriched | Up (p<0.05) | Exosome biogenesis |
| *Tsg101* | Expressed | Modest increase | ESCRT |
| *Cd44* | Expressed | Moderate increase | |
| *Lox* | Expressed | Up | |
| *Loxl1* | ? | ? | Not explicitly detailed |
| *Loxl2* | Modest | ? | Not detailed |
| *Mki67* | Low | No change | Proliferation marker |

**Conclusion for matricellular/coagulation/EV hypothesis:** The gene expression data, as reported, are positive and fulfil the prerequisite for reviving the MK matricellular/secretome axis. *However*, the lack of direct access to the Seurat object for the Tool Use Agent means that the axis remains dependent on those self‑reported results. If they are accurate, the axis has a direct MK‑data anchor. If any error occurred, the axis collapses. Thus, downgrade confidence to “provisional support; requires on‑demand verification.”

---

#### 2. Metabolomics‑derived chains: AMD1‑polyamine (Evo_H1) and Pnp‑inosine/adenosine (Evo_H2)

**Chain for methionine → Amd1 (polyamine):**
- **Metabolite:** Methionine elevated in PH CD41⁺ MKs (log2FC 3.26, from `sFig6A Raw data.xlsx`).  
- **KEGG link:** Amd1 is a **pathway‑neighbor gene** (not direct compound‑enzyme for methionine), mapped through “Cysteine and methionine metabolism” and “Methionine salvage pathway”, with function as S‑adenosylmethionine decarboxylase (polyamine synthesis).  
- **Enzyme gene in MKs:** *Amd1* is MK‑enriched (log2 enrichment 1.353, 31.44% MK+ vs 14.87% other) and significantly upregulated in PH MKs (log2FC 1.77, p=6.55e‑06). This comes from the metabolic evidence context (rank 1 shortlist), not a secondary report.  
- **Literature hits:** Indirect cancer/mTORC1‑polyamine links; no direct pulmonary hypertension or vascular remodeling studies for MK‑Amd1.  
- **Chain strength:** Strong for MK‑specific metabolic enzyme induction; weaker for downstream effect because AMD1 is not a direct methionine‑metabolizing enzyme but a key downstream node.  
- **Evidence for AMD1‑polyamine axis:** Direct metabolite (methionine up in MKs) + direct enzyme gene induction (Amd1 up in MKs) + established pathway logic (polyamine synthesis). The polyamine products (spermidine/spermine) were not measured in the MK metabolomics dataset (no spermidine/spermine rows in sFig6A preview); this is a gap, though the pathway is well accepted.

**Chain for inosine → Pnp (purine/adenosine):**
- **Metabolite:** Inosine elevated in PH CD41⁺ MKs (log2FC 3.82, from `sFig6A Raw data.xlsx`).  
- **KEGG link:** Pnp is a **direct compound‑enzyme** (purine nucleoside phosphorylase, EC:2.4.2.1) that acts on inosine.  
- **Enzyme gene in MKs:** *Pnp* is expressed (20.31% MK+ vs 38.9% other, so not enriched globally) **but** strongly upregulated under PH (log2FC 1.739 in MKs, p=3.81e‑06). Additional enzyme *Nt5c2* also upregulated (log2FC 2.879, p=2e‑04). This is from the metabolic evidence context.  
- **Literature hits:** None retrieved specifically linking MK‑derived inosine to PH; literature on adenosine signalling in PH is abundant but doesn’t trace source to MKs.  
- **Chain strength:** Direct metabolite‑enzyme link, MK hypoxia‑inducible (both *Pnp* and *Nt5c2*). The conversion to adenosine requires additional ecto‑enzymes (CD73), which was not checked in MKs; that is a gap.

**Other shortlist chains (lower readiness):**  
- Amd2: low expression (4.37% MK+) and less significant; not a strong anchor.  
- Dnmt3b: very low expression, not significant differential, no literature – insufficient.  
- Retinoic Acid → Cyp26b1: not significant differential (p=0.253), low readiness – insufficient.

Thus, only the Amd1‑polyamine and Pnp‑inosine chains meet the criteria for direction‑level hypotheses.

**Downstream axis evidence separation:**
- For both Evo_H1 and Evo_H2, the evidence **only supports broad downstream axes** (immune‑mediated, direct vascular‑wall, EV/stromal, thrombo‑inflammatory). The data do not specify which recipient cell type or which exact mediator (e.g., Th17, A2B receptor) dominates.  
- **Candidate downstream axes supported:**  
  - AMD1‑polyamine: *Immune‑mediated* (polyamines modulate T‑cell/macrophage phenotypes), *Direct vascular‑wall* (smooth muscle mitogen), *EV/stromal* (polyamines in extracellular vesicles activating fibroblasts).  
  - Pnp‑inosine: *Immune‑mediated* (adenosine‑driven immunosuppression or T‑cell skewing), *Direct vascular‑wall* (PASMC proliferation via A2B), *Stromal* (fibroblast activation).  
- **Candidate examples that remain provisional:** All specific mediators – spermidine, Th17, IL‑17, A2B receptor, eIF5A hypusination, TGF‑β1 translational control – are noted as **examples** and **not** settled mechanisms. The generation agents correctly labelled them as such.  
- **Evidence needed to resolve the route:**  
  - Spatial proximity of lung MKs to perivascular target cells (immunostaining).  
  - Measurement of polyamine concentrations in perivascular fluid or whole lung.  
  - Inosine‑to‑adenosine conversion capacity by local ecto‑nucleotidases (CD73 expression on MKs or adjacent cells).  
  - Receptor‑blocking experiments on immune cells/vascular cells after MK‑specific gene deletion.

---

#### 3. Whole‑lung metabolomics cross‑check

- **Request:** Check whole‑lung levels of methionine, inosine, spermidine
